PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
Status:
Active, not recruiting
Trial end date:
2024-04-15
Target enrollment:
Participant gender:
Summary
This study is a randomized, open-label, multicentric, phase III trial conducted in patients
receiving aromatase inhibitor and palbociclib as first line therapy for estrogen receptor
(ER)-positive HER2-negative metastatic breast cancer and which aims to evaluate, at the onset
of ESR1 mutations in circulating tumor DNA, the efficacy of a change of the hormone therapy
(aromatase inhibitor (AI) changed to fulvestrant) combined to palbociclib, together with the
safety of hormone therapy and palbociclib combination in the overall population.